Part A-C—Week 52: The most frequently reported TEAEs (in ≥5% of participants overall) were:
injection site reaction (15.6%), injection site erythema (11.7%), injection site pain (6.5%),
headache (6.5%), nasopharyngitis (5.2%), acne (5.2%), and insomnia (5.2%).2
Part B-C—Week 52: The most frequently reported TEAEs (in ≥5% of participants overall) were:
injection site reaction (13.7%), injection site pain (8.4%), injection site erythema (6.6%),
and COVID-19 (7.9%).2

IMPORTANT ATTRIBUTES AND CONSIDERATIONS FOR DUPIXENT1

NO BOXED WARNING

Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information below.

NO KNOWN DRUG-TO-DRUG
INTERACTIONS

  • Not metabolized through the liver or excreted through the kidneys

DUPIXENT IS NOT AN IMMUNOSUPPRESSANT

NO REQUIREMENT FOR INITIAL LAB
TESTING OR ONGOING LAB MONITORING,

according to the Prescribing Information

SELECT IMPORTANT SAFETY INFORMATION

Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme, have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information below.

QW, once weekly; TEAE, treatment-emergent adverse event.

Dosage and administration

Thinking about prescribing DUPIXENT? Find the information you need to get started.

Explore Administration Options